Nexus Investments’ Scale-Up Fund

Hardman & Co

Why Invest

Positives

  • Strategy: To fund fast-growth companies in data, digital, education and healthcare, which have existing products, and support them in scaling up.

Issues

  • Track record: No exits to date from the current set-up, but the unrealised figures show some promise. Nexus Group has had exits from earlier investments.

The Investment Manager

Positives

  • Team: The team has a broad experience in corporate finance, tax and accounting, as well as investment. The Nexus Group also manages a £2.3bn healthcare REIT.

Issues

  • Small team: The team is small, and is dependent on a couple of key people, although it is part of the much larger Nexus Group.

Nuts & Bolts

  • Duration: The fund is expected to have a lifespan of up to eight years, with closings as required.
  • Diversification: The manager expects to provide each investor with 8 to 10 EIS investments, although that range may be exceeded.
  • Valuation: Reviewed twice a year, with updates on progress being sent more frequently.

Specific Issues

  • Fees: A mixture of direct fees and those charged to the investee companies.
  • Performance fee: Charged on a portfolio basis at 20% for returns over £1.

Risks

  • Target returns: The target return is 2.5x capital, which suggests a high-risk investment strategy.
  • Companies: Supplying risk capital to early-stage technology companies at the start of commercialisation. There will be a spread of company returns, as the successful investments will do very well, but those that fail may do so completely.

DOWNLOAD THE FULL REPORT

Share on:

Latest Company News

Meren Energy begins trading on OTCQX Market

Meren Energy Inc. has announced that its common shares are now trading on the OTCQX Best Market in the United States under the ticker symbol MRNFF.

HUTCHMED unveils next-generation ATTC Platform and key R&D advances

HUTCHMED (China) Limited has introduced its next-generation Antibody-Targeted Therapy Conjugate (ATTC) platform and shared major pipeline updates at its 2025 R&D event.

Cerillion to announce FY2025 results on 24 November

Cerillion plc will release its final results for the year ended 30 September 2025 on Monday, 24 November 2025.

Aptamer Group reports strong FY2025 growth and expands Optimer® portfolio

Aptamer Group delivered strong progress in FY2025, achieving a 40% revenue increase and expanding its portfolio of licensable Optimer® assets from four to eleven.

MHA reports 13% revenue growth and confirms full-year outlook

MHA has announced a strong first half for FY26, with revenue rising 13% to £121.3 million and performance in line with market expectations.

Thor Energy advances HY-Range hydrogen and helium exploration

Thor Energy has reported a strategically significant quarter ending September 2025, marked by major progress at its HY-Range hydrogen and helium project in South Australia. The company recorded hydrogen values

    Search

    Search